Recce Pharmaceuticals Ltd (ASX:RCE)
0.5200
-0.0250 (-4.59%)
Jun 3, 2026, 3:59 PM AEST
Recce Pharmaceuticals Revenue
Recce Pharmaceuticals had revenue of 412.04K AUD in the half year ending December 31, 2025, a decrease of -82.70%. This brings the company's revenue in the last twelve months to 974.56K, down -89.84% year-over-year. In the fiscal year ending June 30, 2025, Recce Pharmaceuticals had annual revenue of 7.51M with 49.33% growth.
Revenue (ttm)
974.56K
Revenue Growth
-89.84%
P/S Ratio
161.72
Revenue / Employee
n/a
Employees
n/a
Market Cap
157.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.51M | 2.48M | 49.33% |
| Jun 30, 2024 | 5.03M | 663.14K | 15.19% |
| Jun 30, 2023 | 4.37M | 1.28M | 41.50% |
| Jun 30, 2022 | 3.08M | 1.45M | 88.41% |
| Jun 30, 2021 | 1.64M | 515.66K | 45.97% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 16.28M |
| Starpharma Holdings | 14.58M |
| Orthocell | 9.33M |
| Dimerix | 7.42M |
| Actinogen Medical | 7.36M |
| Alterity Therapeutics | 6.64M |
| Prescient Therapeutics | 4.27M |
| Arovella Therapeutics | 3.21M |
Recce Pharmaceuticals News
- 4 weeks ago - Recce Pharmaceuticals Slides: Corporate presentation - Filings
- 2 months ago - Recce Pharmaceuticals Transcript: Investor update - Transcripts
- 3 months ago - Recce Pharmaceuticals Quarterly report: H1 2026 - Filings
- 7 months ago - Recce Pharmaceuticals Slides: FY 2025 - Filings
- 9 months ago - Recce Pharmaceuticals Annual report: H2 2025 - Filings
- 1 year ago - Recce Pharmaceuticals Slides: Investor Presentation - Filings